Welcome to our dedicated page for Vtv Therapeutics news (Ticker: VTVT), a resource for investors and traders seeking the latest updates and insights on Vtv Therapeutics stock.
vTv Therapeutics Inc. reports developments as a late-stage biopharmaceutical company focused on oral, small-molecule drug candidates for diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a liver-selective glucokinase activator being investigated as an oral adjunctive therapy to insulin for type 1 diabetes. Company updates also reference development work and partnerships across additional chronic-disease candidates, including the PDE4 inhibitor HPP737.
Recurring announcements include clinical and regulatory updates for cadisegliatin, financial results and corporate updates, license and collaboration activity, investor-conference participation, and Nasdaq inducement grants under equity compensation plans. News about vTv often connects pipeline progress with funding arrangements, intellectual property, and business-development agreements that support its drug-development strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cantex Pharmaceuticals, in collaboration with Michigan Medicine, has launched a randomized, double-blind, placebo-controlled study to assess the safety and efficacy of azeliragon for patients hospitalized with COVID-19. This phase 2/3 trial aims to reduce acute kidney injury risks associated with severe COVID-19, leveraging azeliragon's mechanism of blocking the harmful effects of elevated suPAR levels.
Past research has shown suPAR's involvement in severe COVID-19 outcomes. Notably, azeliragon, previously tested for Alzheimer's, exhibited favorable safety profiles in over 2,000 patients. With ongoing trials, Cantex seeks to expand azeliragon's indications beyond cancer treatments to include severe COVID-19 and related kidney complications. This strategic move could potentially enhance the therapeutic landscape for critical COVID-19 conditions.
vTv Therapeutics Inc. (Nasdaq: VTVT) announced key developments, including the initiation of Phase 3 clinical trials for TTP399, an adjunctive treatment for Type 1 diabetes, expected to start in the second half of 2023. The company appointed Steven Tuch as Chief Financial Officer and Elizabeth Keiley as General Counsel, enhancing its executive team. vTv reported a net loss of $4.7 million or $0.06 per share for Q4 2022, a significant reduction from $7.1 million or $0.11 per share in Q4 2021. The total cash position as of December 31, 2022, was $12.1 million, down from $13.4 million in 2021.